00:00
Money for You
Money for You
USD/RUB
EUR/RUB
Market Quotes

GLP-1 drugs weigh on Circle K snack sales

The aisles of convenience stores are changing as shoppers reach for fewer chips and candy bars. Alimentation Couche-Tard, the parent company of Circle K, reports that the rise of weight-loss drugs like Ozempic and Wegovy is directly curbing consumer appetites for high-sugar and high-carbohydrate impulse purchases in the United States.

GLP-1 drugs weigh on Circle K snack sales

U.S. same-store merchandise sales grew by 1.7% during the fiscal first quarter, falling short of the company's 2% to 3% target. Chief Executive Alex Miller confirmed that demand for confectionery and salty snacks softened compared to the previous quarter. Whether this shift represents a permanent change in shopping habits remains unclear, as Miller admitted he does not yet know if the trend is transitory.

To counter the slump, the company is reallocating shelf space, moving away from traditional sweets toward protein-focused and functional snacks. This pivot aligns with a broader strategy to expand fresh food offerings, which now account for 13.2% of total merchandise sales. Despite the snacking decline, the company reported total quarterly revenue of $21.7 billion, exceeding Wall Street expectations of $20.86 billion. Following the report, shares slipped 3% to 81.70 Canadian dollars.

Share

Comments (0)

Leave a comment

No comments yet. Be the first!